Information:
Fel:
ID
34204
Beskrivning
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab; ODM derived from: https://clinicaltrials.gov/show/NCT01943786
Länk
https://clinicaltrials.gov/show/NCT01943786
Nyckelord
Versioner (1)
- 2019-01-15 2019-01-15 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
15 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Colorectal Cancer Metastatic NCT01943786
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
diagnosis of stage iv colorectal adenocarcinoma.
boolean
ID.2
Item
patient ≥ 18 years of age.
boolean
ID.3
Item
ecog ps 0-1
boolean
ID.4
Item
life expectancy ≥ 6 months
boolean
ID.5
Item
candidate for first-line systemic chemotherapy according to regular clinical practice.
boolean
ID.6
Item
measurable disease.
boolean
ID.7
Item
wild-type kras
boolean
ID.8
Item
signed informed consent form.
boolean
ID.9
Item
patient who has received prior chemotherapy for metastatic crc, except for adjuvant treatment completed at least six months before entering study.
boolean
ID.10
Item
patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
boolean